Skip to main content

Tweets

Lancet review of skin cancer risk w/ inflammatory arthritis - both melanoma and Non-melanoma skin cancers are increased in RA & inflammation. Also Package inserts for TNFi say all TNFi Rx pts should have complete skin exams "periodically". Skin cancer screening advised. https://t.co/XddFDe0xh8
Dr. John Cush @RheumNow ( View Tweet )
2 hours 43 minutes ago
“Absence of proof of efficacy does not equal proof of absence of efficacy” - Arthur Kavanaugh, MD

Dr. John Cush @RheumNow ( View Tweet )

6 hours 43 minutes ago
Japanese retrospective study-194 #RA pts Rx w/ JAK inhib (74 vaccinated w/ recombinant zoster (RZV) & 120 Not-Vax). H.zoster lower w/ RZV (4.8/100PY) vs UnVax (7.8/100PY) w/ overall efficacy of 59.1%. RSV Vax pts who got HZ had signif lower lymphocyte #s, higher SDAI & CDAI. https://t.co/vJJRflJ23x
Dr. John Cush @RheumNow ( View Tweet )
8 hours 43 minutes ago
Austrian 1K Paracelsus cohort study; from 9,665, 296 (3.1%) had RA. CKD prevalence was higher in RA vs controls (11.8% vs. 6.7%, p<0.001). Albuminuria was dominant renal dz in RA (6.8% vs 4.2%, p=0.027), but missed signif after adjustments (OR 1.43; 0.96–2.13) https://t.co/9DnErwT4rX
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Evaluation of Rheumatic Complaints https://t.co/cdizOgFqYf https://t.co/YHLAllxpO4
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
FDA has approved nerandomilast (Jascayd) for the treatment of progressive pulmonary fibrosis (PPF) in adults, based on the results of the phase 3 FIBRONEER trial. Nerandomilast is PDE4 inhibitor,, in Oct 2026 it was approved for use in diopathic pulmonary fibrosis (IPF) https://t.co/WVrGj7q7hB
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
2025 Adult Rheumatology Fellowship Match is Strong (Again) The ACR announced today that 2025 Medicine and Pediatric Specialties Match results show rheumatology fellowship positions continuing to fill at high rates. The Match uses a computerized process to pair applicant and https://t.co/ynP46pEKCa
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
ACR: New Data Highlights Urgent Need to Address Arthritis Burden New findings from national U.S. surveys reveal the profound impact of arthritis on millions of adults, especially those facing social and economic challenges. These data will be featured in an upcoming issue of https://t.co/3LlNQ3tx90
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Role of the Nurse in the Care and Management of Rheumatic Diseases - EULAR Review In 2023, a EULAR subcommittee evaluated the roles of nurses and Advanced Practice Nurses (APNs) in arthritis care per EULAR guidelines. Initially proposed in 2012 and revised in 2018, the scope of https://t.co/w1IOQxcACR
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Optimizing Hydroxychloroquine Blood Levels in Lupus A large observational cohort study suggests that monitoring hydroxychloroquine (HCQ) blood levels is effective in systemic lupus erythematosus (SLE) patients with a target therapeutic range (for HCQ level monitoring) of https://t.co/7pggMk2pTO
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
Five Fractures You Don’t Want to Miss In orthopedic practice, missing the wrong fracture can significantly alter a patient’s outcome. Certain injuries may appear subtle on initial imaging yet carry serious consequences if not promptly recognized and managed. https://t.co/zyCRdUkMua
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
Cases & Guidelines: Tuesday Night Rheumatology Panelists discuss their approaches to a range of difficult cases in multiple areas, including RA, PsA and PMR. Panelists: Audrey Gibson, PA-C; Benjamin A. Smith, PA-C; Emma Bavage, ANP; Jack Cush, MD https://t.co/vl5J9NYUKZ https://t.co/nsTf370bu9
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
×